Meatable
Deeptech startups, especially in capital-intensive areas like cultivated meat, must manage capital runway effectively and consider wedge products over moonshots for earlier commercial viability.
Meatable was a Biotechnology/Cultivated Meat startup founded in 2018 in Netherlands. It raised $100M before collapsing in 2025 — 7 years of runway burned. IdeaProof's AI Failure Score: 0/100, driven by commercialization chasm, deeptech complexity, insufficient runway. The shutdown affected employees, investors, and the broader Biotechnology/Cultivated Meat ecosystem. This case study breaks down the timeline, root causes, competitors that won, and replicable lessons for founders validating similar ideas today.
Why did Meatable fail?
Meatable failed in 2025 after 7 years of operation, losing $100M in raised capital. The root cause was commercialization chasm, deeptech complexity, insufficient runway. Key lesson: Deeptech startups, especially in capital-intensive areas like cultivated meat, must manage capital runway effectively and consider wedge products over moonshots for earlier commercial viability.
2018 → 2025
$100M
Biotechnology/Cultivated Meat
Netherlands
Causal Chain
This is our reading of the causal chain — separated from the verifiable facts above. Timeline dates, funding numbers and filings are facts (see methodology); root / proximate / terminal attribution is judgement based on public evidence.
A combination of demand-side, execution, and capital-market pressures that this record documents without isolating a single dominant driver.
- Sector context: Biotechnology/Cultivated Meat in Netherlands, 7 years of runway.
2025: cessation of operations after failing to secure additional capital or a strategic buyer.
Base rates
A single failure is an anecdote. These base rates give you the denominator — how common this outcome is across all startups matching Meatable's profile. Sources are third-party; we do not restate them as our own claims.
of failed startups cite "ran out of cash / could not raise" as the primary trigger — the most common terminal event across cycles.
CB Insights — Top 12 Reasons Startups Fail (2021)of venture-backed consumer hardware startups do not reach a profitable exit within 10 years — hardware requires atypical capital efficiency to survive.
PitchBook Emerging Tech Research (2023)of digital-health startups fail to reach breakeven; reimbursement complexity + regulatory approvals extend runway needs beyond typical VC horizons.
Rock Health State of Digital Health (2023)of startups ultimately fail — including ~10% that fail in the first year and the rest across the following decade.
Startup Genome / CB Insights aggregate (2024)of new US employer businesses survive past their 10th year (Bureau of Labor Statistics BED series).
US Bureau of Labor Statistics — BED (2024)of Series A rounds ever graduate to Series B; the rest run out of runway or pivot without a follow-on.
CB Insights Venture Capital Funnel (2023)Full Analysis
Meatable, a Dutch cultivated meat startup founded in 2018, aimed to revolutionize the meat industry by producing lab-grown pork and beef. They successfully raised $100M from investors like Agronomics and BlueYard, highlighting strong initial interest in their proprietary opti-ox technology for faster cell differentiation. The company targeted both B2B and B2C markets, promising sustainable, ethical meat identical to conventional products. However, Meatable's downfall ultimately stemmed from the immense challenge of scaling complex biotechnological processes from lab to commercial viability within their capital constraints. The gap between proof-of-concept and economically viable production, coupled with the capital-intensive nature of deep-tech, proved insurmountable. The core issue was attempting a 'moonshot' – producing whole-cut meat with high complexity and a long regulatory pathway – rather than focusing on more achievable 'wedge' products. Cultivated meat still faces brutal unit economics that worsen with scale in the short term, requiring significant capital with delayed returns. Meatable's strategy of vertical integration into consumer brands demanded substantial funding and a longer time-to-market, which their $100M, while significant, couldn't sustain against the highly complex challenges of regulatory approval, cost reduction, and industrial-scale bioreactor production. Their failure illustrates the 'commercialization chasm' deep-tech startups often encounter, where technical breakthroughs don't easily translate into market-ready, profitable products. The key lesson from Meatable's trajectory is that even with compelling technology and substantial funding, deep-tech ventures need a strategic, phased approach to commercialization. Instead of immediately targeting complex, high-margin, consumer-facing products, a more sustainable path might involve B2B ingredients or enabling technologies that generate earlier revenue streams and mitigate capital burn. This allows for iterative development, market validation, and the accumulation of intellectual property before tackling the most challenging aspects of a new industry. Meatable's ambitious vision collided with the harsh realities of biotech scalability and financial runway, serving as a cautionary tale for similar ventures in emerging deep-tech sectors.
Could This Failure Have Been Prevented?
IdeaProof's AI validates market demand, competitive positioning, and business model viability in minutes — catching the exact issues that sank Meatable.
Spotted a factual error?
Approved corrections are published in the public changelog with attribution.